Acasti Pharma regains Nasdaq compliance
Insight Weekly: M&A players predict 2023 activity; SPAC IPOs dip; 2022 capacity retirements up
Insight Weekly: Recession risk persists; Banks pull back from crypto; 2022 laggard stocks rally
Highlighting the Top Regional Aftermarket Research Brokers by Sector Coverage
Insight Weekly: Inflation eases; bank M&A slows; top companies boost market share
Acasti Pharma Inc. said it regained compliance with a Nasdaq listing requirement that requires its shares to have a minimum bid price of $1.
The Canada-based developer of cardiovascular prescription drugs received the noncompliance notice in June.
